世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 世界の末期腎不全治療市場レポート、歴史と予測2016-2027年 - カスタマイズ版Global End Stage Renal Disease Treatment Market Report, History and Forecast 2016-2027 - Customized Version 市場の分析と洞察。末期腎不全治療薬の世界市場 この調査レポートは、市場に関する正確で詳細な情報を提供するために、さまざまな方法論と分析を用いて末期腎疾患治療市場を調査しています。より明確に理解する... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー市場の分析と洞察。末期腎不全治療薬の世界市場この調査レポートは、市場に関する正確で詳細な情報を提供するために、さまざまな方法論と分析を用いて末期腎疾患治療市場を調査しています。より明確に理解するために、市場の様々な側面をカバーするためにいくつかのパートに分けられています。そして、読者が各地域の成長の可能性と世界市場への貢献度を理解するのに役立つように、各分野を詳しく解説しています。本レポートでは、研究者が一次および二次的な手法で情報を集約しています。また、同じデータを使って現在の市場シナリオを作成しています。本レポートは、市場に関するより良い、より明確な知識を得るために人々を導くことを目的としています。 COVID-19の流行により、世界の末期腎疾患治療市場規模は2021年に522億3017万米ドルの値を示し、2028年には761億3800万米ドルに再調整され、予測期間2022-2028年にはCAGR5.46%になると予測されています。 世界の末期腎疾患治療薬の範囲とセグメント 世界の末期腎不全治療市場は、企業別、地域（国）別、タイプ別、用途別に分類されています。世界の末期腎疾患治療市場のプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして利用することで、優位に立つことができます。セグメント別分析では、地域（国）別、タイプ別、アプリケーション別の収益と予測に焦点を当て、2017年から2028年までの期間を分析します。 会社別 フレゼニウス ダビタ バクスター ニプロ B. ブラウン 旭化成 日機装 WEGO ニューソル メイヨークリニック 広東省バイオライト メドトロニック 三信メドテック ジャフロンバイオメディカル SWS血液透析ケア 天一医科 種類別セグメント 血液透析 腹膜透析 腎臓移植 用途別セグメント 病院 腎臓透析センター 在宅 その他 地域別 北アメリカ 米国 カナダ アジア太平洋地域 中国 日本 韓国 東南アジア インド オーストラリア 欧州 ドイツ フランス イギリス イタリア ロシア ラテンアメリカ メキシコ ブラジル 中東・アフリカ エジプト サウジアラビア UAE 目次1 MARKET OVERVIEW OF END STAGE RENAL DISEASE TREATMENT 11.1 END STAGE RENAL DISEASE TREATMENT MARKET OVERVIEW 1 1.1.1 END STAGE RENAL DISEASE TREATMENT PRODUCT SCOPE 1 1.1.2 END STAGE RENAL DISEASE TREATMENT MARKET STATUS AND OUTLOOK 1 1.2 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE OVERVIEW BY REGION 2017 VS 2021 VS 2028 3 1.3 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY REGION (2017-2028) 5 1.4 GLOBAL END STAGE RENAL DISEASE TREATMENT HISTORIC MARKET SIZE BY REGION (2017-2022) 5 1.5 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE FORECAST BY REGION (2023-2028) 5 1.6 KEY REGIONS END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 7 1.6.1 NORTH AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 7 1.6.2 EUROPE END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 7 1.6.3 ASIA-PACIFIC END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 8 1.6.4 LATIN AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 8 1.6.5 MIDDLE EAST & AFRICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 9 2 END STAGE RENAL DISEASE TREATMENT MARKET OVERVIEW BY TYPE 10 2.1 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY TYPE: 2017 VS 2021 VS 2028 10 2.2 GLOBAL END STAGE RENAL DISEASE TREATMENT HISTORIC MARKET SIZE BY TYPE (2017-2022) 11 2.3 GLOBAL END STAGE RENAL DISEASE TREATMENT FORECASTED MARKET SIZE BY TYPE (2023-2028) 12 2.4 HEMODIALYSIS 13 2.5 PERITONEAL DIALYSIS 13 2.6 KIDNEY TRANSPLANTATION 14 3 END STAGE RENAL DISEASE TREATMENT MARKET OVERVIEW BY APPLICATION 16 3.1 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY APPLICATION: 2017 VS 2021 VS 2028 16 3.2 GLOBAL END STAGE RENAL DISEASE TREATMENT HISTORIC MARKET SIZE BY APPLICATION (2017-2022) 17 3.3 GLOBAL END STAGE RENAL DISEASE TREATMENT FORECASTED MARKET SIZE BY APPLICATION (2023-2028) 18 3.4 HOSPITALS 19 3.5 KIDNEY DIALYSIS CENTERS 19 3.6 AT HOME 20 3.7 OTHERS 21 4 END STAGE RENAL DISEASE TREATMENT COMPETITION ANALYSIS BY PLAYERS 22 4.1 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY PLAYERS (2017-2022) 22 4.2 GLOBAL TOP PLAYERS BY COMPANY TYPE (TIER 1, TIER 2, AND TIER 3) & (BASED ON THE REVENUE IN END STAGE RENAL DISEASE TREATMENT AS OF 2021) 24 4.3 DATE OF KEY PLAYERS ENTER INTO END STAGE RENAL DISEASE TREATMENT MARKET 25 4.4 GLOBAL TOP PLAYERS END STAGE RENAL DISEASE TREATMENT HEADQUARTERS AND AREA SERVED 26 4.5 KEY PLAYERS END STAGE RENAL DISEASE TREATMENT PRODUCT SOLUTION AND SERVICE 27 4.6 COMPETITIVE STATUS 27 4.6.1 END STAGE RENAL DISEASE TREATMENT MARKET CONCENTRATION RATE 27 4.6.2 MERGERS & ACQUISITIONS, EXPANSION PLANS 29 5 COMPANY (TOP PLAYERS) PROFILES AND KEY DATA 31 5.1 FRESENIUS 31 5.1.1 FRESENIUS PROFILE 31 5.1.2 FRESENIUS MAIN BUSINESS 31 5.1.3 FRESENIUS END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 32 5.1.4 FRESENIUS END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 35 5.1.5 FRESENIUS RECENT DEVELOPMENTS 36 5.2 DAVITA 36 5.2.1 DAVITA PROFILE 36 5.2.2 DAVITA MAIN BUSINESS 37 5.2.3 DAVITA END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 37 5.2.4 DAVITA END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 38 5.2.5 DAVITA RECENT DEVELOPMENTS 38 5.3 BAXTER 38 5.3.1 BAXTER PROFILE 38 5.3.2 BAXTER MAIN BUSINESS 39 5.3.3 BAXTER END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 39 5.3.4 BAXTER END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 41 5.3.5 BAXTER RECENT DEVELOPMENTS 41 5.4 NIPRO 42 5.4.1 NIPRO PROFILE 42 5.4.2 NIPRO MAIN BUSINESS 42 5.4.3 NIPRO END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 42 5.4.4 NIPRO END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 45 5.4.5 NIPRO RECENT DEVELOPMENTS 45 5.5 B. BRAUN 46 5.5.1 B. BRAUN PROFILE 46 5.5.2 B. BRAUN MAIN BUSINESS 46 5.5.3 B. BRAUN END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 47 5.5.4 B. BRAUN END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 50 5.5.5 B. BRAUN RECENT DEVELOPMENTS 50 5.6 ASAHI KASEI 51 5.6.1 ASAHI KASEI PROFILE 51 5.6.2 ASAHI KASEI MAIN BUSINESS 51 5.6.3 ASAHI KASEI END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 51 5.6.4 ASAHI KASEI END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 52 5.6.5 ASAHI KASEI RECENT DEVELOPMENTS 53 5.7 NIKKISO 53 5.7.1 NIKKISO PROFILE 53 5.7.2 NIKKISO MAIN BUSINESS 53 5.7.3 NIKKISO END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 54 5.7.4 NIKKISO END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 56 5.7.5 NIKKISO RECENT DEVELOPMENTS 56 5.8 WEGO 57 5.8.1 WEGO PROFILE 57 5.8.2 WEGO MAIN BUSINESS 57 5.8.3 WEGO END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 57 5.8.4 WEGO END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 59 5.8.5 WEGO RECENT DEVELOPMENTS 59 5.9 NEWSOL 59 5.9.1 NEWSOL PROFILE 59 5.9.2 NEWSOL MAIN BUSINESS 59 5.9.3 NEWSOL END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 60 5.9.4 NEWSOL END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 61 5.9.5 NEWSOL RECENT DEVELOPMENTS 61 5.10 MAYO CLINIC 62 5.10.1 MAYO CLINIC PROFILE 62 5.10.2 MEDIONICS MAIN BUSINESS 62 5.10.3 MEDIONICS END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 63 5.10.4 MEDIONICS END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 63 5.10.5 MEDIONICS RECENT DEVELOPMENTS 63 5.11 GUANGDONG BIOLIGHT 64 5.11.1 GUANGDONG BIOLIGHT PROFILE 64 5.11.2 GUANGDONG BIOLIGHT MAIN BUSINESS 65 5.11.3 GUANGDONG BIOLIGHT END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 65 5.11.4 GUANGDONG BIOLIGHT END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 67 5.11.5 GUANGDONG BIOLIGHT RECENT DEVELOPMENTS 68 5.12 MEDTRONIC 68 5.12.1 MEDTRONIC PROFILE 68 5.12.2 MEDTRONIC MAIN BUSINESS 68 5.12.3 MEDTRONIC END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 69 5.12.4 MEDTRONIC END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 71 5.12.5 MEDTRONIC RECENT DEVELOPMENTS 71 5.13 SANXIN MEDTEC 72 5.13.1 SANXIN MEDTEC PROFILE 72 5.13.2 SANXIN MEDTEC MAIN BUSINESS 72 5.13.3 SANXIN MEDTEC END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 72 5.13.4 SANXIN MEDTEC END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 74 5.13.5 SANXIN MEDTEC RECENT DEVELOPMENTS 74 5.14 JAFRON BIOMEDICAL 74 5.14.1 JAFRON BIOMEDICAL PROFILE 74 5.14.2 JAFRON BIOMEDICAL MAIN BUSINESS 75 5.14.3 JAFRON BIOMEDICAL END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 75 5.14.4 JAFRON BIOMEDICAL END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 76 5.14.5 JAFRON BIOMEDICAL RECENT DEVELOPMENTS 76 5.15 SWS HEMODIALYSIS CARE 77 5.15.1 SWS HEMODIALYSIS CARE PROFILE 77 5.15.2 SWS HEMODIALYSIS CARE MAIN BUSINESS 77 5.15.3 SWS HEMODIALYSIS CARE END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 78 5.15.4 SWS HEMODIALYSIS CARE END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 79 5.15.5 SWS HEMODIALYSIS CARE RECENT DEVELOPMENTS 80 5.16 TIANYI MEDICAL 80 5.16.1 TIANYI MEDICAL PROFILE 80 5.16.2 TIANYI MEDICAL MAIN BUSINESS 80 5.16.3 TIANYI MEDICAL END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 81 5.16.4 TIANYI MEDICAL END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 84 5.16.5 TIANYI MEDICAL RECENT DEVELOPMENTS 84 6 NORTH AMERICA 85 6.1 NORTH AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY (2017-2028) 85 6.2 UNITED STATES 86 6.3 CANADA 87 7 EUROPE 88 7.1 EUROPE END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY (2017-2028) 88 7.2 GERMANY 89 7.3 FRANCE 90 7.4 U.K. 90 7.5 ITALY 91 7.6 RUSSIA 91 8 ASIA-PACIFIC 92 8.1 ASIA-PACIFIC END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY REGION (2017-2028) 92 8.2 CHINA 94 8.3 JAPAN 94 8.4 SOUTH KOREA 95 8.5 SOUTHEAST ASIA 95 8.6 INDIA 96 8.7 AUSTRALIA 96 9 LATIN AMERICA 97 9.1 LATIN AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY (2017-2028) 97 9.2 MEXICO 98 9.3 BRAZIL 99 10 MIDDLE EAST & AFRICA 100 10.1 MIDDLE EAST & AFRICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY 100 10.2 SAUDI ARABIA 101 10.3 UAE 102 10.4 EGYPT 102 10.5 SOUTH AFRICA 103 11 GLOBAL ESRD PATIENTS POPULATION BY MAJOR REGIONS IN 2022 104 12 END STAGE RENAL DISEASE TREATMENT MARKET DYNAMICS 105 12.1 END STAGE RENAL DISEASE TREATMENT INDUSTRY TRENDS 105 12.2 END STAGE RENAL DISEASE TREATMENT MARKET DRIVERS 106 12.3 END STAGE RENAL DISEASE TREATMENT MARKET CHALLENGES 107 12.4 END STAGE RENAL DISEASE TREATMENT MARKET RESTRAINTS 107 13 RESEARCH FINDING/CONCLUSION 108 14 METHODOLOGY AND DATA SOURCE 110 14.1 METHODOLOGY/RESEARCH APPROACH 110 14.1.1 RESEARCH PROGRAMS/DESIGN 110 14.1.2 MARKET SIZE ESTIMATION 110 14.1.3 MARKET BREAKDOWN AND DATA TRIANGULATION 112 14.2 DATA SOURCE 113 14.2.1 SECONDARY SOURCES 113 14.2.2 PRIMARY SOURCES 114 14.3 AUTHOR LIST 115 14.4 DISCLAIMER 116
SummaryMarket Analysis and Insights: Global End Stage Renal Disease Treatment Market Table of Contents1 MARKET OVERVIEW OF END STAGE RENAL DISEASE TREATMENT 11.1 END STAGE RENAL DISEASE TREATMENT MARKET OVERVIEW 1 1.1.1 END STAGE RENAL DISEASE TREATMENT PRODUCT SCOPE 1 1.1.2 END STAGE RENAL DISEASE TREATMENT MARKET STATUS AND OUTLOOK 1 1.2 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE OVERVIEW BY REGION 2017 VS 2021 VS 2028 3 1.3 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY REGION (2017-2028) 5 1.4 GLOBAL END STAGE RENAL DISEASE TREATMENT HISTORIC MARKET SIZE BY REGION (2017-2022) 5 1.5 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE FORECAST BY REGION (2023-2028) 5 1.6 KEY REGIONS END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 7 1.6.1 NORTH AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 7 1.6.2 EUROPE END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 7 1.6.3 ASIA-PACIFIC END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 8 1.6.4 LATIN AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 8 1.6.5 MIDDLE EAST & AFRICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE (2017-2028) 9 2 END STAGE RENAL DISEASE TREATMENT MARKET OVERVIEW BY TYPE 10 2.1 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY TYPE: 2017 VS 2021 VS 2028 10 2.2 GLOBAL END STAGE RENAL DISEASE TREATMENT HISTORIC MARKET SIZE BY TYPE (2017-2022) 11 2.3 GLOBAL END STAGE RENAL DISEASE TREATMENT FORECASTED MARKET SIZE BY TYPE (2023-2028) 12 2.4 HEMODIALYSIS 13 2.5 PERITONEAL DIALYSIS 13 2.6 KIDNEY TRANSPLANTATION 14 3 END STAGE RENAL DISEASE TREATMENT MARKET OVERVIEW BY APPLICATION 16 3.1 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY APPLICATION: 2017 VS 2021 VS 2028 16 3.2 GLOBAL END STAGE RENAL DISEASE TREATMENT HISTORIC MARKET SIZE BY APPLICATION (2017-2022) 17 3.3 GLOBAL END STAGE RENAL DISEASE TREATMENT FORECASTED MARKET SIZE BY APPLICATION (2023-2028) 18 3.4 HOSPITALS 19 3.5 KIDNEY DIALYSIS CENTERS 19 3.6 AT HOME 20 3.7 OTHERS 21 4 END STAGE RENAL DISEASE TREATMENT COMPETITION ANALYSIS BY PLAYERS 22 4.1 GLOBAL END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY PLAYERS (2017-2022) 22 4.2 GLOBAL TOP PLAYERS BY COMPANY TYPE (TIER 1, TIER 2, AND TIER 3) & (BASED ON THE REVENUE IN END STAGE RENAL DISEASE TREATMENT AS OF 2021) 24 4.3 DATE OF KEY PLAYERS ENTER INTO END STAGE RENAL DISEASE TREATMENT MARKET 25 4.4 GLOBAL TOP PLAYERS END STAGE RENAL DISEASE TREATMENT HEADQUARTERS AND AREA SERVED 26 4.5 KEY PLAYERS END STAGE RENAL DISEASE TREATMENT PRODUCT SOLUTION AND SERVICE 27 4.6 COMPETITIVE STATUS 27 4.6.1 END STAGE RENAL DISEASE TREATMENT MARKET CONCENTRATION RATE 27 4.6.2 MERGERS & ACQUISITIONS, EXPANSION PLANS 29 5 COMPANY (TOP PLAYERS) PROFILES AND KEY DATA 31 5.1 FRESENIUS 31 5.1.1 FRESENIUS PROFILE 31 5.1.2 FRESENIUS MAIN BUSINESS 31 5.1.3 FRESENIUS END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 32 5.1.4 FRESENIUS END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 35 5.1.5 FRESENIUS RECENT DEVELOPMENTS 36 5.2 DAVITA 36 5.2.1 DAVITA PROFILE 36 5.2.2 DAVITA MAIN BUSINESS 37 5.2.3 DAVITA END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 37 5.2.4 DAVITA END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 38 5.2.5 DAVITA RECENT DEVELOPMENTS 38 5.3 BAXTER 38 5.3.1 BAXTER PROFILE 38 5.3.2 BAXTER MAIN BUSINESS 39 5.3.3 BAXTER END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 39 5.3.4 BAXTER END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 41 5.3.5 BAXTER RECENT DEVELOPMENTS 41 5.4 NIPRO 42 5.4.1 NIPRO PROFILE 42 5.4.2 NIPRO MAIN BUSINESS 42 5.4.3 NIPRO END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 42 5.4.4 NIPRO END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 45 5.4.5 NIPRO RECENT DEVELOPMENTS 45 5.5 B. BRAUN 46 5.5.1 B. BRAUN PROFILE 46 5.5.2 B. BRAUN MAIN BUSINESS 46 5.5.3 B. BRAUN END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 47 5.5.4 B. BRAUN END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 50 5.5.5 B. BRAUN RECENT DEVELOPMENTS 50 5.6 ASAHI KASEI 51 5.6.1 ASAHI KASEI PROFILE 51 5.6.2 ASAHI KASEI MAIN BUSINESS 51 5.6.3 ASAHI KASEI END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 51 5.6.4 ASAHI KASEI END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 52 5.6.5 ASAHI KASEI RECENT DEVELOPMENTS 53 5.7 NIKKISO 53 5.7.1 NIKKISO PROFILE 53 5.7.2 NIKKISO MAIN BUSINESS 53 5.7.3 NIKKISO END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 54 5.7.4 NIKKISO END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 56 5.7.5 NIKKISO RECENT DEVELOPMENTS 56 5.8 WEGO 57 5.8.1 WEGO PROFILE 57 5.8.2 WEGO MAIN BUSINESS 57 5.8.3 WEGO END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 57 5.8.4 WEGO END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 59 5.8.5 WEGO RECENT DEVELOPMENTS 59 5.9 NEWSOL 59 5.9.1 NEWSOL PROFILE 59 5.9.2 NEWSOL MAIN BUSINESS 59 5.9.3 NEWSOL END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 60 5.9.4 NEWSOL END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 61 5.9.5 NEWSOL RECENT DEVELOPMENTS 61 5.10 MAYO CLINIC 62 5.10.1 MAYO CLINIC PROFILE 62 5.10.2 MEDIONICS MAIN BUSINESS 62 5.10.3 MEDIONICS END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 63 5.10.4 MEDIONICS END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 63 5.10.5 MEDIONICS RECENT DEVELOPMENTS 63 5.11 GUANGDONG BIOLIGHT 64 5.11.1 GUANGDONG BIOLIGHT PROFILE 64 5.11.2 GUANGDONG BIOLIGHT MAIN BUSINESS 65 5.11.3 GUANGDONG BIOLIGHT END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 65 5.11.4 GUANGDONG BIOLIGHT END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 67 5.11.5 GUANGDONG BIOLIGHT RECENT DEVELOPMENTS 68 5.12 MEDTRONIC 68 5.12.1 MEDTRONIC PROFILE 68 5.12.2 MEDTRONIC MAIN BUSINESS 68 5.12.3 MEDTRONIC END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 69 5.12.4 MEDTRONIC END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 71 5.12.5 MEDTRONIC RECENT DEVELOPMENTS 71 5.13 SANXIN MEDTEC 72 5.13.1 SANXIN MEDTEC PROFILE 72 5.13.2 SANXIN MEDTEC MAIN BUSINESS 72 5.13.3 SANXIN MEDTEC END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 72 5.13.4 SANXIN MEDTEC END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 74 5.13.5 SANXIN MEDTEC RECENT DEVELOPMENTS 74 5.14 JAFRON BIOMEDICAL 74 5.14.1 JAFRON BIOMEDICAL PROFILE 74 5.14.2 JAFRON BIOMEDICAL MAIN BUSINESS 75 5.14.3 JAFRON BIOMEDICAL END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 75 5.14.4 JAFRON BIOMEDICAL END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 76 5.14.5 JAFRON BIOMEDICAL RECENT DEVELOPMENTS 76 5.15 SWS HEMODIALYSIS CARE 77 5.15.1 SWS HEMODIALYSIS CARE PROFILE 77 5.15.2 SWS HEMODIALYSIS CARE MAIN BUSINESS 77 5.15.3 SWS HEMODIALYSIS CARE END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 78 5.15.4 SWS HEMODIALYSIS CARE END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 79 5.15.5 SWS HEMODIALYSIS CARE RECENT DEVELOPMENTS 80 5.16 TIANYI MEDICAL 80 5.16.1 TIANYI MEDICAL PROFILE 80 5.16.2 TIANYI MEDICAL MAIN BUSINESS 80 5.16.3 TIANYI MEDICAL END STAGE RENAL DISEASE TREATMENT PRODUCTS, SERVICES AND SOLUTIONS 81 5.16.4 TIANYI MEDICAL END STAGE RENAL DISEASE TREATMENT REVENUE (US$ MILLION) & (2017-2022) 84 5.16.5 TIANYI MEDICAL RECENT DEVELOPMENTS 84 6 NORTH AMERICA 85 6.1 NORTH AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY (2017-2028) 85 6.2 UNITED STATES 86 6.3 CANADA 87 7 EUROPE 88 7.1 EUROPE END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY (2017-2028) 88 7.2 GERMANY 89 7.3 FRANCE 90 7.4 U.K. 90 7.5 ITALY 91 7.6 RUSSIA 91 8 ASIA-PACIFIC 92 8.1 ASIA-PACIFIC END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY REGION (2017-2028) 92 8.2 CHINA 94 8.3 JAPAN 94 8.4 SOUTH KOREA 95 8.5 SOUTHEAST ASIA 95 8.6 INDIA 96 8.7 AUSTRALIA 96 9 LATIN AMERICA 97 9.1 LATIN AMERICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY (2017-2028) 97 9.2 MEXICO 98 9.3 BRAZIL 99 10 MIDDLE EAST & AFRICA 100 10.1 MIDDLE EAST & AFRICA END STAGE RENAL DISEASE TREATMENT MARKET SIZE BY COUNTRY 100 10.2 SAUDI ARABIA 101 10.3 UAE 102 10.4 EGYPT 102 10.5 SOUTH AFRICA 103 11 GLOBAL ESRD PATIENTS POPULATION BY MAJOR REGIONS IN 2022 104 12 END STAGE RENAL DISEASE TREATMENT MARKET DYNAMICS 105 12.1 END STAGE RENAL DISEASE TREATMENT INDUSTRY TRENDS 105 12.2 END STAGE RENAL DISEASE TREATMENT MARKET DRIVERS 106 12.3 END STAGE RENAL DISEASE TREATMENT MARKET CHALLENGES 107 12.4 END STAGE RENAL DISEASE TREATMENT MARKET RESTRAINTS 107 13 RESEARCH FINDING/CONCLUSION 108 14 METHODOLOGY AND DATA SOURCE 110 14.1 METHODOLOGY/RESEARCH APPROACH 110 14.1.1 RESEARCH PROGRAMS/DESIGN 110 14.1.2 MARKET SIZE ESTIMATION 110 14.1.3 MARKET BREAKDOWN AND DATA TRIANGULATION 112 14.2 DATA SOURCE 113 14.2.1 SECONDARY SOURCES 113 14.2.2 PRIMARY SOURCES 114 14.3 AUTHOR LIST 115 14.4 DISCLAIMER 116
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野の最新刊レポート
QYResearch社の分野での最新刊レポート
本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2025/04/18 10:27 143.46 円 163.28 円 193.29 円 |